A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

International Journal of Neuropsychopharmacology

Volumn 17, Issue 10, 2014, Pages 1557-1567

  McIntyre, Roger S ^a   Lophaven, Søren ^b   Olsen, Christina K ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b H LUNDBECK A S   (Denmark)

Author keywords

Cognitive function; Path analysis; Recurrent major depression; Tolerability

Indexed keywords

PLACEBO; VORTIOXETINE; ANXIOLYTIC AGENT; PIPERAZINE DERIVATIVE; SULFIDE;

ADULT; AGED; ARTICLE; ATTENTION; ATTENTION DISTURBANCE; CONTROLLED STUDY; DIGIT SYMBOL SUBSTITUTION TEST; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LEARNING; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESSING SPEED; RANDOMIZED CONTROLLED TRIAL; REY AUDITORY VERBAL LEARNING TEST; TREATMENT DURATION; VELOCITY; ADOLESCENT; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; DEPRESSION; DOSE RESPONSE; INTERNATIONAL COOPERATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; COGNITION DISORDERS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SULFIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938074907     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145714000546     Document Type: Article

References (44)

1. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2012) A double-blind, randomized, placebo-controlled, active-reference study of Lu AA21004 in patients with major depressive disorder (MDD). Int J Neuropsychopharmacol 15:589-600.
2. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54:3206-3221.
3. Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchel D (2010) The role of cognitive impairment in general functioning in major depression. Psychiatry Res 76:183-189.
4. Biringer E, Rongve A, Lund A (2009) A review of modern antidepressants' effects on neurocognitive function. Curr Psych Rev 5:164-174.
5. Booij L, Van der Does AJ, Haffmans PM, Reidel WJ, Fekkes D, Blom MJ (2005) The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients. J Psychopharmacology 19:267-275.
6. Boulenger JP, Loft H, Olsen CK (2014) Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 29:138-149.
7. Buist-Bouwman MA, Ormel J, de Graaf R, de Jonge P, van Sonderen E, Alonso J, Bruffaerts R, Vollebergh WA; ESEMeD/MHEDEA 2000 investigators (2008) Mediators of the association between depression and role functioning. Acta Psychiatr Scand 118:451-458.
8. Campbell S, Macqueen G (2004) The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29:417-426.
9. Cohen J (1988) Statistical power analysis for the behavioral sciences, Second Edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers.
10. Dale E, Zhang H, Plath N, Sanchez C (2013) Vortioxetine's (Lu AA21004) memory enhancing properties in preclinical rat models may involve an increase of pyramidal cell output - rat hippocampal slice study. Biol Psychiatry 73 (Suppl. 9):213S.
11. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL (2014) Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 24:160-171.
12. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64:1465-1475.
13. Greer TL, Kurian BT, Trivedi MH (2010) Defining and measuring functional recovery from depression. CNS Drugs 24:267-284.
14. Hammar A, Ardal G (2009) Cognitive functioning in major depression - a summary. Front Hum Neurosci 3:26. doi: 10.3389/neuro.09.026.2009.
15. Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM (2002) Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl) 163:106-110.
16. Henigsberg N, Mahableshwarkar A, Jacobsen P, Chen Y, Thase ME (2012) A randomized, double-blind, placebo-controlled 8-week trial of the ef ficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 73:953-959.
17. ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice (1996) http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm073122.pdf.
18. Jaeger J, Berns S, Uzelac S, Davis-Conway S (2006) Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 145:39-48.
19. Jensen JB, du Jardin KG, Song D, Budac D, Smagin G, Sanchez C, Perhson AL (2013) Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct serotonin receptor modulation. Acta Neuropsychiatrica 25 (Suppl. 1):20.
20. Katona C, Hansen T, Olsen CK (2012) A randomized, doubleblind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215-223.
21. Laughren T (2006) Food and Drug Administration, Center for Drug Evaluation and Research. Memorandum on Suicidality. 16-Nov-2006. http://www.fda.gov/ohrms/dockets/ac/06/ briefing/2006-4272b1-01-fda.pdf.
22. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC (1997) The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224-231.
23. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA (2012) A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord 140:113-124.
24. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, Alsuwaidan M, Baskaran A (2013) Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 30:515-527.
25. Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbol TB (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharm Exp Ther 340:666-675.
26. Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C (2013) Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 105:41-50.
27. Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF, Neumeister A (2011) Reduced ventral striatal/ ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl) 213:547-553.
28. Naismith SL, Longley WA, Scott EM, Hickie IB (2007) Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 7:32.
29. Pehrson AL, Sanchez C (2013) Serotonergic modulation of the glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr Aug 1:1-13. doi: 10.1017/S1092852913000540.
30. Pehrson AL, Cremers T, Bétry C, van der Hart MGC, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C (2013a) Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters - a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 23:133-145.
31. Pehrson AL, Li Y, Haddjeri N, Gulinello M, Sanchez C (2013b) Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms. Eur Neuropsychopharm 23 (Suppl. 2):S196-S197.
32. Porter RJ, Bourke C, Gallagher P (2007) Neuropsychological impairment in major depression: its nature, origin and clinical significance. Aust NZ J Psychiatry 41:115-128.
33. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900-909.
34. Rock PL, Roiser JP, Riedel WJ, Blackwell AD (2013) Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 1-12. doi: 10.1017/S0033291713002535.
35. Rockwood K (2004) Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75:677-685.
36. Rund BR, Sundet K, Asbjornsen A, Egeland J, Landro NI, Lund A, Roness A, Stordal KI, Hugdahl K (2006) Neuropsychological test profiles in schizophrenia and nonpsychotic depression. Acta Psychiatr Scand 113:350-359.
37. Sanchez C, Robichaud PJ, Pehrson A, Leiser SC (2012) The effects of the multimodal antidepressant Lu AA21004 on attention and vigilance measured as EEG activity in the rat. Eur Neuropsychopharmacol 22 (Suppl. 2):S243-S244.
38. Streiner DL (2005) Finding our way: an introduction to path analysis. Can J Psychiatry 50:115-122.
39. Svendsen AM, Kessing LV, Munkholm K, Vinberg M, Miskowiak KW (2012) Is there an association between subjective and objective measures of cognitive function in patients with affective disorders? Nord J Psychiatry 66:248-253.
40. United States Food and Drug Administration (FDA) (2010) Guidance for industry: suicidality: prospective assessment of occurrence in clinical trials, September 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm315156.htm.
41. Westrich L, Pehrson A, Zhong H, Nielsen SM, Frederiksen K, Stensbøl TB, Boyle N, Hentzer M, Sanchez C (2012) In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract 16 (Suppl. 1):47.
42. World Medical Association (WMA) (2008) Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/.
43. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N (2008) Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res 42:797-801.
44. Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA (2012) Why do some depressed outpatients who are not in remission according to the Hamilton depression rating scale nonetheless consider themselves to be in remission? Depress Anxiety 29:891-895.